BioSpace News Archive

Altamira Therapeutics Ltd. today announced that the first patient has been randomized in its trial for the clinical evaluation of Bentrio (AM-301) in seasonal allergic rhinitis.

Since launching in late summer 2021, the innovative Bigfoot Unity™ Diabetes Management Program and its Bigfoot Clinic Hub™ are demonstrating that technology can help transform how health care professionals manage their patient populations on multiple daily injections of insulin.

Philadelphia-based National Disease Research Interchange announces the election of Paul M. Lieberman, Ph.D., to its Board.

BioSig Technologies, Inc. today announced the appointment of Gray Fleming as Chief Commercial Officer.

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it received Pandemic Special Access Route (PSAR) authorization from the Health Sciences Authority (HSA) for the Cue COVID-19 Test for self-testing in Singapore.

Paragonix Technologies, the leading hypothermic donor organ preservation provider, announced the first-in-human clinical use of the investigational NRP-DCD Method by the University of Nebraska Medical Center to recover a donor heart and transport it utilizing the Paragonix SherpaPak® System.

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021.

enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced a poster presentation at the upcoming Society of Urologic Oncology Annual Meeting being held from December 1 to December 3, 2021.

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication of a study funded by the Bill & Melinda Gates Foundation and in collaboration with AMANHI (Alliance for Maternal and Newborn Health Improvement).

Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next generation capsid inhibitor, AB-836.